Clinical Trial Detail

NCT ID NCT02181218
Title Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors Washington University School of Medicine
Indications

peripheral T-cell lymphoma

diffuse large B-cell lymphoma

Hodgkin's lymphoma

Therapies

Pegfilgrastim

romidepsin

Gemcitabine + Oxaliplatin + Dexamethasone

Age Groups: adult

No variant requirements are available.